Clinical Trials
9
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study
- Conditions
- HIV -1 Infection
- Interventions
- First Posted Date
- 2025-10-10
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- TaiMed Biologics Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT07215468
TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals
- Conditions
- HIV-1-infection
- Interventions
- Drug: TMB-365/TMB-380
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2025-10-22
- Lead Sponsor
- TaiMed Biologics Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT05275998
- Locations
- 🇺🇸
Quest Clinical Research, San Francisco, California, United States
🇺🇸CAN Community Health, Fort Lauderdale, Florida, United States
🇺🇸Midway Immunology and Research Center, Ft. Pierce, Florida, United States
Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants
- Conditions
- HIV-1-infection
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- TaiMed Biologics Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04027387
- Locations
- 🇺🇸
Quest Clinical Research, San Francisco, California, United States
🇺🇸Midway Immunology and Research Center, Fort Pierce, Florida, United States
🇺🇸Orlando Immunology Center, Orlando, Florida, United States
Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection
- First Posted Date
- 2019-04-12
- Last Posted Date
- 2025-10-20
- Lead Sponsor
- TaiMed Biologics Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT03913195
- Locations
- 🇺🇸
Anthony Mills MD Inc., Los Angeles, California, United States
🇺🇸Gary Richmond MD, PA, Fort Lauderdale, Florida, United States
🇺🇸Orlando Immunology Center, Orlando, Florida, United States
Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- TaiMed Biologics Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03110549
- Locations
- 🇺🇸
Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States
- Prev
- 1
- 2
- Next